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Despite intensive studies, the mechanisms of cytokine receptor activation are still not completely understood.
Historically two models have been proposed: early studies suggested a mechanism involving ligand-induced di-
merization of the receptors which results in the activation of downstream signaling pathways, whereas, in the ab-
sence of ligands, the receptors are thought to be in a monomeric inactive state; later studies uncovered evidence
for the existence of many receptors as inactive preformed dimers, which upon ligand binding undergo confor-
mational changes and/or relative rotation of the receptor molecules. Here we focus on the dimerization status of
the single chain cytokine receptors, which are involved in the regulation of hematopoiesis.
Keywords: cytokine receptors, dimerization, hematopoiesis.
Cytokine receptor family. Cytokines are a large group
of polypeptide growth factors that bind to their cognate
receptors and mediate intracellular signaling events lea-
ding to the modulation of gene expression. Most cytoki-
ne receptors consist of a multi- or disubunit complex: a
unique and specific ligand-binding chain and a signal-
transducing subunit, which may be structurally similar
to other members of the cytokine receptor superfamily
[1, 2]. Type I cytokine receptors can be organized into
subgroups by the number of receptor subunits and the
use of common signaling chains: single chain family of
the receptors; the common  chain (c) family; gp130
family and the common  chain (c) family (Fig. 1). Ty-
pe II cytokine receptors are always heterodimers and in-
clude interferon receptors. The single chain cytokine re-
ceptor subfamily includes receptors for growth hormo-
ne (GH), prolactin (PRL), erythropoietin (EPO), granu-
locyte-colony-stimulating factor (GCSFR) and throm-
bopoietin (TpoR). These receptors share some common
structural features: cytokine receptor homology domain
(CRH) which can be divided into two sub-domains of
approximately 100 amino acids (namely D1 for N-ter-
minal part) and the membrane distal sub-domain (name-
ly D2); WSXWS motif at the C-end of D2 domain,
which was shown to be important for the folding and
traffic of the receptors; Box1 (proline-rich motif) and
Box2 (hydrophobic part) in the intracellular domain of
the receptors are conserved and important for JAK2 bin-
ding and signal transduction [3–6] (Fig. 1).
Cytokine receptors lack intrinsic kinase activity
and rely on the activation of cytoplasmic Janus kinase
(JAKs) family proteins that are recruited onto their in-
tracellular domains [7]. Cytokine binding to the recep-
tor extracellular domain elicits a conformational change
which rearranges the preformed dimers or promotes the
dimer or oligomer formation from monomeric chains
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[8]. This conformation is transmitted to the cytosolic
juxta-membrane receptor domain, which brings into
close proximity the active and catalytic loops of JAKs
enabling them to trans-phosphorylate and activate each
other [9]. The activated JAKs phosphorylate the tyro-
sine residues on receptor cytosolic tails, which recruit
several signaling substrates, including, in the first pla-
ce, the members of the signal transducer and activator
of transcription (STAT) family [10].
Since conformational changes in pre-formed dimer
or dimerization of two monomer subunits by ligand are
two most probable mechanisms of the receptor activa-
tion, application of different techniques is important for
the investigation of cytokine receptors dimerization.
Table briefly summarizes different techniques, which
were applied to study dimerization of single chain cyto-
kine receptors.
GrowthHormoneReceptor (GHR). GH is thema-
jor regulator of postnatal growth. GH binds to its recep-
tor (GHR) providing somatogenic, metabolic and diffe-
rentiative effects. GHR was the first receptor of class l
cytokine receptors to be cloned. The crystal structures
of the bound and unbound forms have been solved sug-
gesting that two receptor subunits bind one molecule of
hormone [11]. Two distinct sites within GH molecule
engage two GHR extracellular domains at nearly iden-
tical contact points on each receptor [11]. Studies on hu-
man GHR by co-immunoprecipitation of differently
epitope-tagged receptors showed that GHR exists as a
ligand-independent dimer [12]. Further studies using
fluorescence resonance energy transfer (FRET) and
bioluminescence resonance energy transfer (BRET)
confirmed that the receptor subunits undergo specific
transmembrane interaction independent of hormone
binding. An activation mechanismwas proposed where
the change of conformation in pre-formed dimer activa-
tes downstream signaling in response to the hormone
binding [13, 14]. Binding of the hormone to the pre-
formed GHR dimer realigns two receptor subunits by
rotation and closer apposition, followed by a juxtaposi-
tion of the catalytic domains of the associated tyrosine-
protein kinase JAK2 below the cell membrane. Ato-
mistic molecular dynamics simulations have been used
to explore the conformational changes linked to the bin-
ding of human growth hormone (hGH) to the extracellu-
lar domains of the human growth hormone receptor
(hGHR) suggesting that hormone binding induces the
GHR subunit rotation [15]
Prolactin Receptor (PrlR). Prolactin was first
shown to stimulate lactation during pregnancy and mam-
mary gland development, but further investigations ha-
ve proven it to be important in the water and electrolyte
balance, growth and development, metabolic functions,
immunoregulation and also some neuroendocrine func-
tions [16]. Unlike GHR,where one gene encodes a sing-
le transcript, several isoforms of PrlR are generated by
alternative splicing [17]. The structure of the extracel-
lular domains of these isoforms appeared to be identi-
cal but the length of intracellular domains different. Si-
milar to GHR, two PrlRs have been proven to bind one
Prl molecule by engaging two different sites. The Prl
molecule was believed to first recruit one PrlRmonomer
through its binding site 1, thus forming an inactive com-
plex, followed by the addition of another receptor mo-
nomer to the binding site 2 of the ligand and activate the
complex.
However, the later studies showed that PrlR existed
as a preformed dimer on cell membranes, but receptor
predimerization is insufficient to trigger signaling in the
absence of a ligand [18, 19]. Only upon ligand binding,
the receptor undergoes a conformational change to acti-
vate the downstream signaling pathways. The structure
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Fig. 1. Schematic representation of type I cytokine receptors subgroups
of 2:1 complex between the ECD of two rat PrlR and the
human Prl was solved in 2010 [20].
Granulocyte-Colony-Stimulating Factor Receptor.
GCSFR, or as it has recently been renamed, CSF3R, the
main hematopoietic growth factor that controls neutro-
phil development. Besides, GCSF plays an important
part in the so-called «emergency granulopoiesis» by en-
hancing the numbers and functions of the neutrophils in
response to bacterial infections. Both effects are accom-
plished by inducing the proliferation and survival of the
myeloid precursors, followed by a cell cycle arrest and
neutrophilic differentiation [21]. The crystal structure
of a 2:2 complex involving human GCSF and the CRM
domain of mouse GCSFR has been published in 1999
[22]. Although this structure revealed a significant infor-
mation concerning the ligand-receptor interactions, it
failed to clarify the mechanism of the receptor activa-
tion, as the complex did not contain the original Ig-like
domain normally present in the receptor. In 2005, the
crystal structure of a complex between hGCSF and the
Ig-like and CRM (Ig–CRM) domains of human GCSFR
(hGCSFR) at 2.8- resolution was reported [23]. The
2:2 receptor:ligand signaling complex was obtained by
using crossover interactions involving the Ig-like do-
main of hGCSF-R and the neighboring hGCSF, in a two-
fold axis of crystallographic symmetry. This structure
is rather distinct from that of the heterogeneous mouse
GCSF-R complex [22] resembling more closely the 2:
2:2 active complex of human interleukin-6, hIL-6 recep-
tor and human gp130 (the last cytokine receptor is a sha-
red signal transducing unit for several cytokines) [24],
and the 2:2 assembly of viral IL-6 and human gp130
[25], rather than the other homodimeric receptors of its
subgroup. The Ig-like domain crossover conformation
required for GCSFR activation was in agreement with
the earlier reports based on the mutational and thermo-
dynamic analyses [26].
Erythropoietin receptor (EpoR ). Epo together with
its receptor (EpoR) are involved in the production of
erythrocytes [27]. Epo or EpoR knock-out mice die at
embryo day 12,5 of severe anaemia [28]. However, the
recent studies highlighted additional roles of Epo and
its receptor in non-hematopoietic processes such as an-
giogenesis and wound healing [29, 30]. Dimerization
of the receptor was highlighted as an important feature
of the EpoR activation mechanism. The most studied
phenomenon that supports this observation is the consti-
tutively active EpoR mutant, which has a point substi-
tution of arginine to cysteine (EpoR R129C) in the ex-
tracellular domain, which was shown to induce inter-
monomeric disulfide bond formation and activation [31].
The studies of EpoR dimerization by bivalent anti-
bodies against the EpoR extracellular domain [32], or
Epo-mimetic peptides [33], analysis of chimeric recep-
tor molecules [34] or by employing biochemical stu-
dies of the purified EpoR extracellular region [35] sup-
ported the idea that receptor homodimerization is an im-
portant step in the activation process. The data suppor-
ting this idea were also obtained from the 3-dimensio-
nal structure analyses of the EpoR extracellular region
bound to the Epo or erythropoietic peptide agonists.
The EpoR:Epo complex is a dimeric receptor occupied
by a single Epo molecule in a 2:1 ratio [36, 37]. Full-
length EpoR on the cell surface was shown to be a pre-
formed dimer as well as short forms of EpoR [38, 39].
Mainly the transmembrane domain mediates dimeriza-
tion of EpoR in the absence of ligand [38]. The study of
the Epo:EpoR complex revealed that Epo has 2 discrete
binding sites in EpoRwith different affinities to Epo [40].
Thus, Epo binds asymmetrically to EpoR dimer.
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Assays applied Receptor studied Reference
Co-immunoprecipitation GHR, PrlP [12, 18]
Immunofluorescence
Co-Patching
EpoR [51]
Structural studies (NMR,
crystallography)
GHR, PrlR,
GSFR, EpoR
[11, 19, 20, 22,
23, 35, 36]
Sedimentation equilibrium
analytical ultracentrifugation
EpoR, TpoR [50, 52]
TOXCAT TpoR [49]
FRET (Foster Resonance
energy Transfer)
GHR [13]
BRET (Bioluminescence
Resonance energy transfer)
GHR, PrlR [13, 19]
Cross-linking TpoR [53]
Complementation of
dihydrofolate reductase
EpoR [39]
Gaussia princeps luciferase
complementation
EpoR, TpoR [50]
Techniques applied to study the dimerezitaion of single chain
cytokine receptors
Thrombopoiein receptor (TpoR). Thrombopoietin
and its receptor, Mpl (TpoR), are the primary regula-
tors of megakaryocytopoiesis and play a critical role in
the hematopoietic stem biology [41, 42]. Upon ligand
binding, Mpl facilitates tyrosine phosphorylation of cy-
toplasmic signaling proteins and activation of several
signaling pathways, including JAK-STAT, MAPK and
PI3K [43, 44]. TpoR is a major regulator of megakaryo-
poiesis and platelet formation, but is also required for
maintaining the quiescence of hematopoietic stem cells,
regulating proliferation of early myeloid progenitors
[45, 46]. The structural modelling and ligand binding
affinity experiments showed that first 280 amino acids
of the extracellular domain of TpoR are responsible for
the Tpo binding and possibly for preventing the rest of
the receptor from signaling in the absence of the ligand
[47]. The crystal structure of any extracellular part of
TpoR is not available so far. Nevertheless, the crystal
structure of the receptor-binding domain of human Tpo
coupled with a neutralizing Fab fragment was solved in
2004 [48].
The experiments using titration calorimetry show-
ed that human Tpo interacts with soluble Tpo receptor
containing the extracellular cytokine receptor homology
domains in 1:2 stoichiometry.
Therefore, the model for the activation of TpoR is
similar to other single chain receptors. Resent studies
confirmed that the transmembrane domain of TpoR and
full length TpoR form homodimers in a ligand-in-
dependentmanner [49, 50], although at lower levels than
EpoR.
Most of the studies showed that single chain recep-
tors on the plasma membrane form dimers before ligand
binding. This implies that conformational changes are
required in preformed dimers to activate downstream
signaling upon ligand binding. However, it could not be
excluded, that the receptors exist in monomeric and di-
meric forms on the cell surface and the ligand could bind
to both of them at the same time promoting complex ac-
tivation. The equilibrium might exist between mono-
meric and dimeric forms, and high levels of expression
might displace the equilibrium towards the dimeric form.
What appears certain is that even at high expression le-
vels and near-complete ligand-independent dimeriza-
tion, the receptors are designed to remain inactive in the
absence of cytokine stimulation.
Full understanding of the cytokine receptor activa-
tion is a major challenge for the future, as well as appli-
cation of new techniques to investigate the dimeriza-
tion issue.
Ìåõàí³çìè àêòèâàö³¿ ìîíîìåðíèõ ðåöåïòîð³â öèòîê³í³â:
ë³ãàíä-íåçàëåæíà òà ë³ãàíä-³íäóêàâàíà äèìåðèçàö³ÿ
Â. C. Ãðèøêîâà, Ð. ². Àëáó, Ñ. Í. Êîíñòàíòèíåñêó
Ðåçþìå
Íåçâàæàþ÷è íà ³íòåíñèâí³ äîñë³äæåííÿ, ìåõàí³çìè àêòèâàö³¿ öè-
òîê³íîâèõ ðåöåïòîð³â íàðàç³ º íå çîâñ³ì çðîçóì³ëèìè. ²ñòîðè÷íî
áóëî çàïðîïîíîâàíî äâ³ ìîäåë³: ó ðàíí³õ ðîáîòàõ ïðèïóñêàëè ìå-
õàí³çì ë³ãàíä-³íäóêîâàíî¿ äèìåðèçàö³¿ ðåöåïòîð³â, ùî ïðèçâîäèòü
äî àêòèâàö³¿ á³ëüø ï³çí³õ ñèãíàëüíèõ øëÿõ³â, ó òîé ÷àñ ÿê çà â³ä-
ñóòíîñò³ ë³ãàíä³â ðåöåïòîðè ïåðåáóâàþòü ó ìîíîìåðîìó íåàê-
òèâîâàíîìó ñòàí³; ïîäàëüøèìè äîñë³äæåííÿìè âèÿâëåíî äîêàçè
³ñíóâàííÿ áàãàòüîõ ðåöåïòîð³â ó ôîðì³ íåàêòèâîâàíèõ ñôîðìîâà-
íèõ äèìåð³â, ÿê³ ïðè çâ’ÿçóâàíí³ ë³ãàíäà çàçíàþòü êîíôîðìàö³é-
íèõ çì³í òà/àáî ìîíîìåðè ÿêèõ ïî÷èíàþòü ðîòàö³éíî ïåðåì³ùó-
âàòèñÿ â³äíîñíî îäèí îäíîãî. Äàíèé îãëÿä ñôîêóñîâàíî íà ïðîá-
ëåì³ äèìåðèçàö³¿ îêðåìèõ ãîìîäèìåðíèõ ðåöåïòîð³â öèòîê³í³â,
ÿê³ ïðè÷åòí³ äî ðåãóëÿö³¿ êðîâîòâîðåííÿ.
Êëþ÷îâ³ ñëîâà: ðåöåïòîðè öèòîê³í³â, äèìåðèçàö³ÿ, ãåìà-
òîïîåç.
Ìåõàíèçìû àêòèâàöèè ìîíîìåðíûõ ðåöåïòîðîâ öèòîêèíîâ:
ëèãàíä-íåçàâèñèìàÿ è ëèãàíä-èíäóöèðîâàííàÿ äèìåðèçàöèÿ
Â. C. Ãðèøêîâà, Ð. È. Àëáó, Ñ. Í. Êîíñòàíòèíåñêó
Ðåçþìå
Íåñìîòðÿ íà èíòåíñèâíûå èññëåäîâàíèÿ, ìåõàíèçìû àêòèâàöèè
öèòîêèíîâûõ ðåöåïòîðîâ äî ñèõ ïîð íå ïîëíîñòüþ èçó÷åíû. Èñ-
òîðè÷åñêè áûëî ïðåäëîæåíî äâå ìîäåëè: ðàííèå ðàáîòû ïðåäïî-
ëàãàëè ìåõàíèçì ëèãàíä-èíäóöèðîâàííîé äèìåðèçàöèè ðåöåïòî-
ðîâ, ÷òî ïðèâîäèò ê àêòèâàöèè áîëåå ïîçäíèõ ñèãíàëüíûõ ïóòåé, â
òî âðåìÿ êàê ïðè îòñóòñòâèè ëèãàíäîâ ðåöåïòîðû íàõîäÿòñÿ â
ìîíîìåðíîì íåàêòèâíîì ñîñòîÿíèè; ïîñëåäóþùèå èññëåäîâàíèÿ
âûÿâèëè äîêàçàòåëüñòâà ñóùåñòâîâàíèÿ ìíîãèõ ðåöåïòîðîâ â
ôîðìå íåàêòèâèðîâàííûõ ñôîðìèðîâàííûõ äèìåðîâ, êîòîðûå ïðè
ñâÿçûâàíèè ëèãàíäà ïðåòåðïåâàþò êîíôîðìàöèîííûå èçìåíåíèÿ
è/èëè ìîíîìåðû êîòîðûõ íà÷èíàþò ðîòàöèîííî ïåðåìåùàòüñÿ
îòíîñèòåëüíî äðóã äðóãà. Äàííûé îáçîð ñôîêóñèðîâàí íà ïðîáëå-
ìå äèìåðèçàöèè îòäåëüíûõ ãîìîäèìåðíèõ ðåöåïòîðîâ öèòîêè-
íîâ, âîâëå÷åííõ â ðåãóëÿöèþ êðîâåòâîðåíèÿ.
Êëþ÷åâûå ñëîâà: ðåöåïòîðû öèòîêèíîâ, äèìåðèçàöèÿ, ãåìà-
òîïîåç.
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